Identifying Key Benefits in European Off-Patent Biologics and Biosimilar Markets: It is Not Only About Price!
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1179-190X
- Extent
-
Online-Ressource
- Language
-
Englisch
- Notes
-
online resource.
- Bibliographic citation
-
Identifying Key Benefits in European Off-Patent Biologics and Biosimilar Markets: It is Not Only About Price! ; day:2 ; month:12 ; year:2019 ; pages:1-12
BioDrugs ; (2.12.2019), 1-12
- Classification
-
Wirtschaft
- Creator
-
Dutta, Binita
Huys, Isabelle
Vulto, Arnold G.
Simoens, Steven
- Contributor
-
SpringerLink (Online service)
- DOI
-
10.1007/s40259-019-00395-w
- URN
-
urn:nbn:de:101:1-2020032520074108725912
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
14.08.2025, 11:03 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Dutta, Binita
- Huys, Isabelle
- Vulto, Arnold G.
- Simoens, Steven
- SpringerLink (Online service)
Other Objects (12)
Clinical and regulatory perspectives on biosimilar therapies and intended copies of biologics in rheumatology
The Global Landscape of Manufacturers of Follow-on Biologics: An Overview of Five Major Biosimilar Markets and 15 Countries
Biologics in therapy
Retention Rate and Safety of Biosimilar CT-P13 in Rheumatoid Arthritis: Data from the Korean College of Rheumatology Biologics Registry
Identifying Program Benefits When Participation Is Misreported
Moderne Antipsoriatika : Schwerpunkt Biologics
Biologics in der Dermatologie
Adverse reactions to biologics
Biologics in der Dermatologie
Biosimilar-to-Biosimilar Switching: What is the Rationale and Current Experience?
AVT02: An Adalimumab Biosimilar
SB8: A Bevacizumab Biosimilar
Clinical and regulatory perspectives on biosimilar therapies and intended copies of biologics in rheumatology
The Global Landscape of Manufacturers of Follow-on Biologics: An Overview of Five Major Biosimilar Markets and 15 Countries
Biologics in therapy
Retention Rate and Safety of Biosimilar CT-P13 in Rheumatoid Arthritis: Data from the Korean College of Rheumatology Biologics Registry
Identifying Program Benefits When Participation Is Misreported
Moderne Antipsoriatika : Schwerpunkt Biologics
Biologics in der Dermatologie
Adverse reactions to biologics
Biologics in der Dermatologie
Biosimilar-to-Biosimilar Switching: What is the Rationale and Current Experience?
AVT02: An Adalimumab Biosimilar
SB8: A Bevacizumab Biosimilar
Clinical and regulatory perspectives on biosimilar therapies and intended copies of biologics in rheumatology
The Global Landscape of Manufacturers of Follow-on Biologics: An Overview of Five Major Biosimilar Markets and 15 Countries
Biologics in therapy
Retention Rate and Safety of Biosimilar CT-P13 in Rheumatoid Arthritis: Data from the Korean College of Rheumatology Biologics Registry
Identifying Program Benefits When Participation Is Misreported
Moderne Antipsoriatika : Schwerpunkt Biologics
Biologics in der Dermatologie
Adverse reactions to biologics
Biologics in der Dermatologie
Biosimilar-to-Biosimilar Switching: What is the Rationale and Current Experience?
AVT02: An Adalimumab Biosimilar